Last updated: May 26, 2026
ecutive summary: VANOS (fluocinonide) is a topical corticosteroid cream with supply chains that typically rely on a small number of API and finished-dose manufacturers plus contract manufacturing for branded product packaging, labeling, and distribution. A definitive, supplier-by-supplier map requires VANOS-specific sourcing disclosures (NDA/CMC, DMF holders, Orange Book manufacturers, and FDA BLA/NDA labeling) that are not provided here.
Which companies supply VANOS (fluocinonide) cream, and who are the drug product manufacturers?
Answer: The drug product supplier/manufacturer list for VANOS is determined from the FDA Orange Book “Applicant/Manufacturer” fields and the US prescribing information’s “Manufactured for/Distributed by” statements.
Where to find the VANOS manufacturer identity in US filings
- Orange Book listing fields for VANOS (active ingredient: fluocinonide; dosage form: topical cream).
- Prescribing information (US label): “Manufactured for” and “Distributed by” lines.
- Facility names tied to the firm via FDA labeling and compliance records.
What “supplier” can mean for VANOS
- API supplier (fluocinonide).
- Contract manufacturer for drug product (cream formulation, mixing, filling, packaging).
- Labeler/distributor (commercial supply).
What are the fluocinonide API suppliers used for VANOS, and who holds relevant DMFs?
Answer: Fluocinonide API sourcing is typically controlled through DMFs and/or qualified supplier programs. VANOS-specific DMF holders are only identifiable from the Orange Book and FDA DMF cross-references to the NDA.
API supplier identification paths
- Orange Book references to the NDA/Applicant and listed dosage-form strength.
- DMF listings correlated to the NDA’s approval and change history.
- Public inspection history for fluocinonide API facilities (when linked to the NDA supply chain).
How strong is the VANOS manufacturing and supply chain, and how concentrated are suppliers?
Answer: Concentration risk for topical corticosteroids depends on whether the API is commoditized or constrained by specific polymorph/purity and whether finished-dose production requires specialized equipment for emulsions/creams.
Supply concentration drivers for topical corticosteroids
- API grade specifications (impurities, polymorphic form where relevant).
- Sterility is not required for typical cream manufacture, but contamination control and emulsion stability are critical.
- Scale and packaging format constraints (tube vs jar, lot-based QA).
Who supplies VANOS packaging, labeling, and finished goods logistics (CDMO vs labeler)?
Answer: Finished-dose packaging and labeling are usually handled by the approved manufacturer and/or a contract packager; logistics can be handled by the same firm or a third-party distributor.
Packaging and labeling components that affect suppliers
- Tube filling or case packing.
- Overwrap, carton labeling, NDC labeling.
- Serialized labeling requirements if applicable to the product’s commercial distribution.
Which contract manufacturers (CDMOs) make VANOS cream for the brand owner?
Answer: CDMO identity must be sourced from VANOS’s labeling/manufacturing statement and FDA CMC submissions tied to the approved product.
Common CDMO disclosure signals
- “Manufactured by” or “Manufactured for” manufacturer name on the US label.
- NDC-specific labeler and packager on the NDC directory.
- Facility identifiers that appear across multiple branded topicals.
What are the Orange Book listings for VANOS, and what do they show about suppliers?
Answer: Orange Book listings show the applicant and the specific manufacturers tied to the approved dosage form.
Orange Book fields that matter for supplier mapping
- Applicant/Holder (NDA owner).
- “Manufacturers” (listed by NDC and dosage form).
- Patent and exclusivity records (not suppliers directly, but often tied to product submissions that include CMC).
What risks exist if VANOS suppliers change, and how does that affect availability?
Answer: Supplier changes can trigger:
- CMC comparability evaluations.
- Stability requalification for the finished cream.
- Lot release delays due to analytical method transfers or revised manufacturing controls.
Availability risk channels
- API lead-time constraints.
- Contract manufacturing capacity shifts during peak demand.
- Regulatory holds if inspection outcomes or batch deviations occur.
How do VANOS suppliers compare with other topical fluocinonide products?
Answer: Competitive product supply chains for other fluocinonide topicals can differ in:
- API procurement terms.
- Cream base formulation (vehicle compatibility).
- Packaging and NDC labeler identity.
What to compare in practice
- Orange Book manufacturer/apparent labeler.
- Labeling “manufactured for” names.
- NDC directory manufacturer/labeler fields.
Key Takeaways
- “Suppliers for VANOS” splits into API sourcing (fluocinonide) and finished-dose manufacturing/labeling.
- The authoritative supplier list is determined from Orange Book “Applicant/Manufacturer” entries plus the “Manufactured for/Distributed by” lines on VANOS labeling.
- Without VANOS-specific Orange Book/NDC/label data in the prompt, a supplier-by-supplier list cannot be produced from first principles.
FAQs
- How do I identify the NDC labeler and packager for VANOS cream?
- Does VANOS use the same fluocinonide API supplier as other branded topical corticosteroids?
- What FDA Orange Book fields are most useful for mapping VANOS manufacturing sites?
- Can a CDMO manufacture VANOS cream under a “manufactured for” label, and how is that disclosed?
- What CMC steps occur when switching VANOS API or finished-dose manufacturers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
